

CORRECTION

Open Access



Correction: Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial

Emma J. A. Schepens^{1,2*}, Esther E. Blijleven^{1,2}, Wilbert M. Boek³, Sanne Boesveldt⁴, Robert J. Stokroos^{1,2}, Inge Stegeman^{1,2} and Digna M. A. Kamalski^{1,2}

Correction: *BMC Medicine* 20, 445 (2022)
<https://doi.org/10.1186/s12916-022-02625-5>

The original article [1] contained the following errors with their respective amendments:

1) Abstract, lines 48 and 49:

“Median TDI score on SST was 26.8 (IQR 23.6-29.3) in the placebo group and 28.8 (IQR 24.0-30.9) in the prednisolone group, with a median difference of 2.0 (95% CI 0.75 to 1.5).”

to

“Median TDI score on SST was 26.8 (IQR 23.6-29.3) in the placebo group and 28.8 (IQR 24.0-30.9) in the prednisolone group, with a median difference of - 1.5 (-3.0 to 0.25).”

2) Outcome, line 233-235:

“Median TDI score was 26.8 (IQR 23.6- 29.3) in the placebo group and 28.8 (IQR 24.0- 30.9) in the prednisolone group, with a median difference of 2.0 (95% CI 0.75 to 1.5, $p = 0.10$).”

to

“Median TDI score was 26.8 (IQR 23.6- 29.3) in the placebo group and 28.8 (IQR 24.0- 30.9) in the prednisolone group, with a median difference of - 1.5 (-3.0 to 0.25).”

3) Line 237-238:

“Self-reported smell function on VAS-score was 3.2 (IQR 1.8- 6.5) in the placebo group and 3.6 (IQR 1.0- 5.8) in the prednisolone group with a median difference of 0.45 (95% CI 1.1 to -1.2, $p = 0.53$).”

to

“Self-reported smell function on VAS-score was 3.2 (IQR 1.8- 6.5) in the placebo group and 3.6 (IQR 1.0- 5.8) in the prednisolone group with a median difference of 0.3 (95% CI -0.9 to -1.3, $p = 0.53$).”

4) Line 240-242:

“Self-reported taste function on VAS-score was 5.6 (IQR 2.3- 7.6) in the placebo group and 5.0 (IQR 2.0- 7.8) in the prednisolone group with a median difference of 0.25 (95% CI 0.1 to -0.2, $p = 0.80$).”

to

“Self-reported taste function on VAS-score was 5.6 (IQR 2.3- 7.6) in the placebo group and 5.0 (IQR 2.0- 7.8) in the prednisolone group with a median difference of 0.1 (95% CI -1.0 to 1.3, $p = 0.80$).”

The original article can be found online at <https://doi.org/10.1186/s12916-022-02625-5>.

*Correspondence:

Emma J. A. Schepens

e.j.a.schepens-2@umcutrecht.nl

¹ Department of Otorhinolaryngology- Head and Neck Surgery, University Medical Center Utrecht, P.O. Box 85500, 3508, GA, Utrecht, The Netherlands

² Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands

³ Department of Otorhinolaryngology- Head and Neck Surgery, Hospital Gelderse Vallei, Ede, The Netherlands

⁴ Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 16 February 2023

Reference

1. Schepens EJA, Blijleven EE, Boek WM, Boesveldt S, Stokroos RJ, Stegeman I, et al. Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial. *BMC Medicine*. 2022;20:445. <https://doi.org/10.1186/s12916-022-02625-5>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

